Newcastle University

Qualifications

BPharm
PhD

Memberships

British Association of Cancer Research
International Society of Magnetic Resonance in Medicine

Research Interests

Magnetic Resonance Imaging and Spectroscopy
Positron Emission Tomography

• Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, Stirling JJ, Sena L, Padhani AR, Rustin GJ. Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance Imaging. Journal of Clinical Oncology 2003, 21(15), 2831-2842.
• Nielsen FU, Daugaard P, Bentzen L, Stodkilde-Jorgensen H, Overgaard J, Horsman MR, Maxwell RJ. Effect of Changing Tumor Oxygenation on Glycolytic Metabolism in a Murine C3H Mammary Carcinoma Assessed by in Vivo Nuclear Magnetic Resonance Spectroscopy. Cancer Research 2001, 61(13), 5318-5325.
• Maxwell RJ, Prise VE, Vojnovic B, Rustin GJ, Lodge MA, Tozer GM, Wilson J. Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR in Biomedicine 2002, 15(2), 89-98.
• Seddon BM, Maxwell RJ , Grimshaw R, Raynaud F, Tozer GM, Workman P, Honess DJ. Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy. Clinical Cancer Research 2002, 8(7), 2323-2335.
• Breidahl T, Nielsen FU, Stodkilde-Jorgensen H, Maxwell RJ, Horsman MR. The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: acomparative assessment using MRI and MRS. Acta Oncologica 2006, 45(3), 306-316.
• Haagensen EJ, Kyle S, Beale GS, Maxwell RJ, Newell DR. The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. British Journal of Cancer 2012, 106(8), 1386-1394.
• Chatterjee S, Frew J, Wilsdon JB, McCallum H, Mott J, Stevenson P, Dobrowsky W, Maxwell RJ, Nutting CM, Kelly CG. Final Results of Vortigern Study: CT Versus Pet-CT Based Tomotherapy Voluming and Dose Escalation in Oropharyngeal Squamous Cell Carcinoma (ISRCTN 33175361, UKCRN ID: 08/h0907/127) [meeting abstract]. Clinical Oncology 2011, 23(3), S26-S26.